drugset / Trial / NCT00352469

Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety

NCT00352469

Phase 4 Completed 20 enrolled Creighton University AstraZeneca · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Alcohol use disorders (AUDs) are a major problem facing our society. Their treatment is complex, and involves multiple behavioral and pharmacotherapy interventions. There are 3 approved medications for AUDs, but their efficacy for AUDs that co-exist with anxiety disorders is unknown. This study explores the effects of the medication, sustained-release quetiapine fumarate (Seroquel SR) for the treatment of alcohol dependence and co-morbid anxiety. Primary outcome measure is the amount of alcohol used. Secondary outcome measures include craving for alcohol, length of sobriety from drinking and level of anxiety with Seroquel SR.

Timeline

Start
2006-02
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 300 mg
Comparator Quetiapine Small molecule 400 mg